Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of diseases that range from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. In addition, the burden of NAFLD is rapidly growing. Previously, NAFLD was regarded as a hepatic manifestation of metabolic syndrome, which is a traditional cardiovascular disease (CVD) risk factor. However, there has been an increasing evidence that suggest NAFLD to be an independent risk factor of CVD. Therefore, currently, NAFLD should be reconsidered as not only a simple manifestation of metabolic syndrome, but also a systemic disease that contribute to CVD. There are some reasonable hypotheses about the relationship between NAFLD and CVD. Moreover, many studies have been performed to better understand this relationship. Nonetheless, the underlying mechanisms and pathogenesis of NAFLD that contribute to CVD have not yet been fully elucidated to date. This review focuses on the underlying mechanisms and relationship between NAFLD and CVD. 
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The Korean Journal of Gastroenterology 34, 35 Portal hypertension affecting the systemic vascular resistance Metalloproteinase 38 Decreased elastic fiber and increased collagen in media of the large arteries increased arterial stiffness VEGF [39] [40] [41] [42] Instability of atheroma 43, 44 HMGB-1 45 Involving in Systemic inflammation and angiogenesis Dysfunction of endothelial cells ADMA 47 Increased arterial wall stiffness EMPs 48, 49 Increased EMPs which are products of endothelial destruction Endothelial progenitor cell 48, 49 Decreased endothelial progenitor cells which indicating endothelial repair function Inflammation and cytokine IL-1b 50 , IL-6 51,52 hs-CRP, TNF-a, CCL3, sICAM-1 51, 53 Inflammation markers increased in NAFLD Homocysteine and inflammation Hyperhomocysteinemia [58] [59] [60] Oxidative stress, Decreased NO synthesis, Involving hepatic fibrosis Hepatokine and insulin resistance FetA 65 Increased inflammatory cytokine and insulin resistance and decreased adiponectin 65 Decreased vascular calcification by inhibiting TGF-β1signal pathway 65 FGF-21 [66] [67] [68] Increased level of FGF-21 for compensating insulin resistance in NAFLD SeP 69, 70 Involving in Insulin resistance, hs-CRP, increased intimal thickness of carotid artery Lipid profiles TG, LDL, small dense LDL particles (LDL3, LDL4) 73 Increased in NAFLD, contributing to atherogenesis HDL 72 A defending factor of atherogenesis, but decrease in NAFLD. oxLDL 77 Contributing to oxidative stress in NASH and hepatic fibrosis Coagulation factors Factor 8, 9, 10, 12 78 Increased in NAFLD PAI-1 79, 80 Increased in NAFLD Increasing in proportion to degree of fibrosis in NAFLD Protein C 81 Decreased in NAFLD Liver-gut axis TMAO 86 By increasing activity of FMO, the level of TMAO increases and which contributes to atherogenesis in NAFLD. GLP-1, GIP 88 Blood glucose regulating hormones, which secreted from the GI tract, decrease in NAFLD. Genetics PNPLA3 92 Involved in histologic severity of NAFLD, The association with CVD is not clear TM6SF2 92 Involved in hepatic fibrosis Inhibiting CVD by promoting intrahepatic TG and cholesterol storage and inhibition of secretion of VLDL and TG ADMA, asymmetric dimethyl arginine; CCL3, Chemokine (C-C motif) ligand 3; CVD, cardiovascular disease; EMPs, endothelial microparticles; FetA, fetuin-A; FGF21, fibroblast growth factor 21; FMO, flavin monooxygenase; GI, gastrointestinal; GIP, gastric inhibitory protein; GLP-1, glucagon-like peptide; HDL, high-density lipoproteins; HMGB-1, high mobility group box 1; hs-CRP, high sensitivity C-reactive protein; IL-1b, interleukin 1b; IL-6, interleukin 6; LDL, low-density lipoproteins; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NO, nitric oxide; oxLDL, oxidized low-density lipoprotein; PAI-1, plasminogen activator inhibitor 1; PNPLA3, patatin-like phospholipase domain containing protein 3; SeP, selenoprotein P; sICAM, soluble intercellular adhesion molecule-1; TG, triglyceride; TGF-β, transforming growth factor beta; TM6SF2, transmembrane 6 superfamily member 2; TMAO, trimethylamine-N-Oxide; TNF-a, tumor necrosis factor a; VEGF, vascular endothelial growth factor; VLDL, very low-density lipoproteins. Table 1) .
